麻豆传媒

Experts discuss importance of both physician- and patient-reported domains

Roundtable of experts weigh in on "unprecedented" efficacy, and safety issues

Favorable results with TAK-279 and deucravacitinib in studies at ACR

Andrew Blauvelt, MD, leads a roundtable discussion with Melinda Gooderham, MSc, MD, and Neil Korman, MD

Andrew Blauvelt, MD, leads a discussion with Melinda Gooderham, MD, MSc, and Neil Korman, MD, PhD

An expert roundtable discussion on guselkumab and risankizumab

Andrew Blauvelt, MD, leads a discussion with Melinda Gooderham, MD, MSc, and Neil Korman, MD, PhD

Our expert roundtable discusses patient-physician discordance and the need for tracking PROs

Our expert roundtable looks at possible clinical/demographic predictors, or biomarkers

Our expert roundtable discusses promising results from two studies on TYK2/JAK1 inhibitors

Our expert roundtable discusses the long-term efficacy and safety of the IL-23 inhibitor